Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme
Abstract Introduction In 2023, recombinant zoster vaccine (RZV) replaced zoster vaccine live (ZVL) vaccine in the UK National Immunisation Programme (NIP) for prevention of herpes zoster (HZ). The vaccination age was reduced from 70 to 65 years, with a subsequent planned reduction to 60 years. This...
Saved in:
Main Authors: | Manjit Hunjan, Desmond Curran, Alen Marijam, Yasmeeta Vekria, Nikolaos Giannelos |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-11-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40121-024-01073-3 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on “Parabolic Changes in Pain Scores Among Partial Herpes Zoster Patients: A Retrospective Study” [Letter]
by: Tan Y, et al.
Published: (2025-01-01) -
A cross-sectional study exploring the predictors of herpes zoster vaccination for people aged over 50 years old in Chaoyang district, Beijing
by: Jiao Zhang, et al.
Published: (2025-01-01) -
Herpes zoster after left nephroureterectomy for renal carcinoma: a case report
by: Yuren Zhang, et al.
Published: (2025-01-01) -
Low vitamin D3 levels may be associated with herpes zoster
reactivation
by: Göktürk Dere, et al.
Published: (2024-11-01) -
Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017–April 2024
by: Yamin Shu, et al.
Published: (2025-02-01)